ArticlePharmacoEconomics - open2022

Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months.

Andrew Blauvelt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.